Influence of CYP3A4, CYP3A5, and NR3C1 genes polymorphism on the effectiveness of glucocorticoid therapy in patients with endocrine ophthalmopathy

Close metadata

PURPOSE

To study the possibilities of pharmacogenetic testing for the polymorphism of the glucocorticoid receptor gene NR3C1 and cytochrome P450 in predicting the effectiveness of glucocorticoid therapy in patients with edematous exophthalmos — one of the clinical forms of endocrine ophthalmopathy.

MATERIAL AND METHODS

The results of glucocorticoid therapy were analyzed in 75 patients with different clinical forms of endocrine ophthalmopathy aged 27 to 84 years. All patients underwent standard ophthalmological examination, external examination of the eye with assessment of the state of periorbital tissues, determination of the shape and size of the palpebral fissure (vertical size), position of the eye in orbit, Hertel exophthalmometry, ultrasound scanning and computed tomography of the orbits. Genetic analysis of the polymorphism of the studied genes was carried out using real-time polymerase chain reaction (real-time PCR).

RESULTS

The study did not find patterns in the distribution of homo- and heterozygous genotypes of A6986G polymorphic markers of the CYP3A5 gene, 6 C>T intron of the CYP3A4 gene and rs6190 of the NR3C1 gene in patients with endocrine ophthalmopathy and their effect on the glucocorticoid response (p>0.05).

CONCLUSION

Results of pharmacogenetic testing of the gene for the glucocorticoid receptor NR3C1 and cytochrome P450 do not provide a reliable confirmation of the influence of the polymorphism of the studied genes on the effectiveness of glucocorticoid therapy in patients with endocrine ophthalmopathy.

Keywords:

endocrine ophthalmopathy

glucocorticoid therapy

glucocorticoid receptor gene polymorphism

cytochrome P450 system

resistance

Authors:

A.F. Brovkina

Russian Medical Academy of Continuous Professional Education

D.A. Sychev

Russian Medical Academy of Continuous Professional Education

O.S. Toropova

Russian Medical Academy of Continuous Professional Education

Received:

23.05.2020

Accepted:

13.07.2020

List of references:

Smith TJ. Pathogenesis of Graves’ orbitopathy: A 2010 update. J Endocrinol Invest. 2010;33(6):414-421. https://doi.org/10.1007/BF03346614
Perros P, Hegedüs, Bartalena L, Marcocci C, Kahaly GJ, Baldeschi L, Salvi M, Lazarus JH, Eckstein A, Pitz S, Boboridis K, Anagnostis P, Ayvaz G, Boschi A, Brix TH, Currò N, Konuk O, Marinò M, Mitchell AL, Stankovic B, Törüner FB, von Arx G, Zarković M, Wiersinga WM. Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement. Orphanet J Rare Dis. 2017;12:72-74. https://doi.org/10.1186/s13023-017-0625-1
Vannucchi G, Covelli D, Campi I, Origo D, Curro N, Cirello V, Dazzi D, Beck-Peccoz P, Salvi M. The therapeutic outcomes of intravenous steroids therapy for active Graves orbitopathy is influenced by the time of response but not polymorph of the glucocorticoid receptor. Eur J Endocrinol. 2013; 170(1):55-61. https://doi.org/10.1530/EJE-13-0611
Abraham-Nordling M, Byström K, Törring O, Lantz M, Berg G, Calissendorff J. Incidence of hyperthyroidism in Sweden. Eur J Endocrinol. 2011; 165:899-905. https://doi.org/10.1530/EJE-11-0548
Zaletel K, Gaberscek S, Pirnat E. Ten-year follow-up of thyroid epidemiology in Slovenia after increase in salt iodization. Croat Med J. 2011;52:615-621. https://doi.org/10.3325/cmj.2011.52.615
Tanda ML, Piantanida E, Liparulo L, Veronesi G, Lai A, Sassi L, Pariani N, Gallo D, Azzolini C, Ferrario M, Bartalena L. Prevalence and natural history of Graves’ orbitopathy in a large series of patients with newly diagnosed Graves’ hyperthyroidism seen at a single center. J Clin Endocrinol Metab. 2013;98:1443-1449. https://doi.org/10.1210/jc.2012-3873
Brent GA. Graves’ Disease. N Engl J Med. 2008;358(24):2594-2605. https://doi.org/10.1056/NEJMcp0801880
Wang Y, Smith TJ. Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy. Invest Ophthalmol Vis Sci. 2014;55(3):1735-1748. https://doi.org/10.1167/iovs.14-14002
Lehmann GM, Garcia-Bates TM, Smith TJ, Feldon SE, Phipps RP. Regulation of lymphocyte function by PPARγ: relevance to thyroid eye disease-related inflammation. PPAR Res. 2008;2008:895-901. https://doi.org/10.1155/2008/895901
Khong JJ, McNab AA, Ebeling PR, Craig JE, Selva D. Pathogenesis of thyroid eye disease: review and update on molecular mechanisms. Br J Ophthalmol. 2016;100(1):142-150. https://doi.org/10.1136/bjophthalmol-2015-307399
Smith TJ. TSH-receptor-expressing fibrocytes and thyroid-associated ophthalmopathy. Nat Rev Endocrinol. 2015;11(3):171-181. https://doi.org/10.1038/nrendo.2014.226
Liang C, Du W, Dong Q, Liu X, Li W, Wang Y, Gao G. Expression levels and genetic polymorphisms of interleukin-2 and interleukin-10 as biomarkers of Graves’ disease. Exp Ther Med. 2015;9(3):925-930. https://doi.org/10.3892/etm.2015.2180
Mysliwiec J, Palyga I, Nikolajuk A, Kowalska A, Gorska M. Serum interleukin-16 and RANTES during treatment of Graves’ orbitopathy with corticosteroids and teleradiotherapy. Endokrynol Pol. 2012;63(2):92-96.
Kaback LA, Smith TJ. Expression of hyaluronan synthase messenger ribonucleic acids and their induction by interleukin-1beta in human orbital fibroblasts: potential insight into the molecular pathogenesis of thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 1999;84(11):4079-4084. https://doi.org/10.1210/jcem.84.11.6111
Tsui S, Fernando R, Chen B, Smith TJ. Divergent Sp1 levels may underlie differential expression of UDP glucose dehydrogenase by fibroblasts: Role in susceptibility to orbital Graves’ disease. J Biol Chem. 2011;286(27):24487-24499. https://doi.org/10.1074/jbc.M111.241166
Goh MS, McNab AA. Orbital decompression in Graves’ orbitopathy: efficacy and safety. Intern Med J. 2005;35(10):586-591. https://doi.org/10.1111/j.1445-5994.2005.00933.X
Brovkina AF, Stoyukhina AS. Classification of endocrine ophthalmopathy. Problemy endocrinologii. 2006;52(5):11-14 (In Russ.).
Stiebel-Kalish H, Robenshtok E, Hasanreisoglu M, Ezrachi D, Shimon I, Leibovici L. Treatment modalities for Graves’ ophthalmopathy: systematic review and meta-analysis. J Clin Endocrinol Metab. 2009;94(8):2708-2716. https://doi.org/10.1210/jc.2009-0376
Tachibana S, Murakami T, Noguchi H, Noguchi Y, Nakashima A, Ohyabu Y, Noguchi S. Orbital magnetic resonance imaging combined with clinical activity score can improve the sensitivity of detection of disease activity and prediction of response to immunosuppressive therapy for Graves’ ophthalmopathy. Endocr J. 2010;57(10):853-861. https://doi.org/10.1507/endocrj.k10e-156
Dolman PJ. Evaluating Graves’ orbitopathy. Best Pract Res Clin Endocrinol Metab. 2012;26(3):229-248. https://doi.org/10.1016/j.beem.2011.11.007
Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersinga WM. The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy Guidelines for the Management of Graves’ Orbitopathy. Eur Thyroid J. 2016;5(1):9-26. https://doi.org/10.1159/000443828
Turck N, Eperon S, De Los Angeles G, Obéric A, Hamédani M. Thyroid-Associated Orbitopathy and BiomaMarkers: Where We Are and What We Can Hope for the Future. Dis Markers. 2018;2018:7010196. https://doi.org/10.1155/2018/7010196
Brovkina AF. Recent aspects of pathogenesis and treatment of endocrinous ophthalmopathy. Vestnik Rossiyskoy akademii meditsinskikh nauk. 2003;(5): 52-54. (In Russ.).
Bahn RS. Pathophysiology of Graves’ ophthalmopathy: the cycle of disease. J Clin Endocrinol Metab. 2003;88(5):1939-1946. https://doi.org/10.1210/jc.2002-030010
Romero-Kusabara IL, Filho JV, Scalissi NM, Melo KC, Demartino G, Longui CA, Melo MR, Cury AN. Distinct inflammatory gene expression in extraocular muscle and fat from patients with Graves’ orbitopathy. Eur J Endocrinol. 2017;176(4):481-488. https://doi.org/10.1530/EJE-16-0945
Łacheta D, Miśkiewicz P, Głuszko A, Nowicka G, Struga M, Kantor I, Poślednik KB, Mirza S, Szczepański MJ. Immunological Aspects of Graves’ Ophthalmopathy. Biomed Res Int. 2019;2019:7453260. https://doi.org/10.1155/2019/7453260
Nunery WR, Martin RT, Heinz GW, Gavin TJ. The association of cigarette smoking with clinical subtypes of ophthalmic Graves’ disease. Ophthalmic Plast Reconstr Surg. 1993;9(2):77-82. https://doi.org/10.1097/00002341-199306000-00001
Brovkina AF, Aubakirova AS, Yatsenko OYu, Moslekhi Sh. Lipogenic type of edematous exophthalmos: clinical picture, treatment. Vestnik oftal’mologii. 2008;(2):28-30 (In Russ.).
Brovkina AF, Karmazanovsky GG, Yatsenko OYu. Changes in Retrobulbar fat and Muscles at Patients with Edematous Exophthalmus from the Point of View of a Computed Tomography. Zhurnal Meditsinskaya vizualizatsiya. 2007;(4):7-10 (In Russ.).
Brovkina AF. Endokrinnaya oftal’mopatiya [Endocrine ophthalmopathy]. M.: GEOTAR-Med; 2004. (In Russ.).
Koumas L, Smith TJ, Feldon S, Blumberg N, Phipps RP. Thy-1 Expression in Human Fibroblast Subsets Defines Myofibroblastic or Lipofibroblastic Phenotypes. Am J Pathol. 2003;163(4):1291-1300. https://doi.org/10.1016/S0002-9440(10)63488-8
Khoo TK, Coenen MJ, Schiefer AR, Kumar S, Bahn RS. Evidence for enhanced Thy-1 (CD90) expression in orbital fibroblasts of patients with Graves’ophthalmopathy. Thyroid. 2008;18(12):1291-1296. https://doi.org/10.1089/thy.2008.0255
Li H, Fitchett C, Kozdon K, Jayaram H, Ros GEE, Bailly M, Ezra DG. Independent Adipogenic and Contractile Properties of Fibroblasts in Graves’ Orbitopathy: An In Vitro Model for the Evaluation of Treatments. PLoS One. 2014;9(4):e95586. https://doi.org/10.1371/journal.pone.0095586
Kahaly GJ, Shimony O, Gellman YN, Lytton SD, Eshkar-Sebban L, Rosenblum N, Refaeli E, Kassem SIlany J, Naor D. Regulatory T-cells in Graves’ orbitopathy: baseline findings and immunomodulation by anti-T lymphocyte globulin. J Clin Endocrinol Metabolism. 2011;96(2):422-429. https://doi.org/10.1210/jc.2010-1424
Oakley RH, Cidlowski JA. The Biology of the Glucocorticoid Receptor: New Signaling Mechanisms in Health and Disease. J Allergy Clin Immunol. 2013; 132(5):1033-1044. https://doi.org/10.1016/j.jaci.2013.09.007
Murai T, Reilly CA, Ward RM, Yost GS. The inhaled glucocorticoid fluticasone propionate efficiently inactivates cytochrome P450 3A5, a predominant lung P450 enzyme. Chem Res Toxicol. 2010;23(8):1356-1364. https://doi.org/10.1021/tx100124k
Sychev DA, Ashraf G Md, Svistunov AA. The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo. Drug Des Devel Ther. 2018;12:1147-1156. https://doi.org/10.2147/DDDT.S149069
Orlovsky MA. Allelic polymorphism of glucocorticoid receptor NR3C1 (GR): from molecular biology to clinical implications. Biopolym Cell. 2012;28(5): 338-351. https://doi.org/10.7124/bc.000061
Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci. 2004;25(4):193-200. https://doi.org/10.1016/j.tips.2004.02.007
Molnár Á, Patócs A, Likó I, Nyírő G, Rácz K, Tóth M, Sármán B. An unexpected, mild phenotype of glucocorticoid resistance associated with glucocorticoid receptor gene mutation case report and review of the literature. BMC Med Genet. 2018;19(1):37. https://doi.org/10.1186/s12881-018-0552-6
Tompkins LM, Wallace AD. Mechanisms of cytochrome P450 induction. J Biochem Mol Toxicol. 2007;21(4):176-181. https://doi.org/10.1002/jbt.20180
Stockmann C, Fassl B, Gaedigk R, Nkoy F, Uchida DA, Monson S, Reilly CA, Leeder JS, Yost GS, Ward RM. Fluticasone Propionate Pharmacogenetics: CYP3A4*22 Polymorphism and Pediatric Asthma Control. J Pediatr. 2013;162(6):1222-1227. https://doi.org/10.1016/j.jpeds.2012.11.031
Zaletova NK, Chukhlovin AB, Tretjak AT, Vostokova LP, Kornienko EA. Genetic factors modifying response to glucocorticoid treatment in chronic pediatric inflammatory bowel diseases. Pediatr. 2015:6(3);91-97 (In Russ.).
Quax RAM, Koper JW, Huisman AM, Weel A, Hazes JMW, Lamberts SWJ, Feelders RA. Polymorphisms in the glucocorticoid receptor gene and in the glucocorticoid-induced transcript 1 gene are associated with disease activity and response to glucocorticoid bridging therapy in rheumatoid arthritis. Rheumatol Int. 2015;35(8):1325-1333. https://doi.org/10.1007/s00296-015-3235-z
Ito A, Okada Y, Hashita T. Sex Differences in the Blood Concentration of Tacrolimus in Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients with CYP3A5*3/*3. Biochem Genet. 2017;55(3):268-277. https://doi.org/10.1007/s10528-017-9795-8
Lane S, Lee T. Mechanisms of corticosteroid resistance in asthmatic patients. Int Arch Allergy Immunol. 1997;113:193-195. https://doi.org/10.1159/000237544
Panek M, Pietras T, Kupryś-Lipińska I. The analysis of the factors influencing the development of glucocorticoid resistance in the etiopathogenesis of severe bronchial asthma. Postepy Biochemii. 2010;56(4):373-382.
Saakyan SV, Panteleyeva OG, Batyrbekova FH, Sirmays OS, Martirosyan NS, Petunina NA, Tsygankov AYu, Loginov VI, Burdenny AM. Genetic Factors of Glucocorticoid Resistance in Patients with Grave’s Ophthalmopathy. Effektivnaya farmakoterapiya. 2019;15(33):18-23. (In Russ.). https://doi.org/10.33978/2307-3586-2019-15-33-18-23
Brovkina AF, Zhukova OD. Endocrine myopathy is one of the clinical forms of endocrine ophthalmopathy. Prakticheskaya meditsina. 2016;2(94):17-21. (In Russ.).
Boyle B, Korányi K, Patocs A, Liko I, Szappanos A, Bertalan R, Racz K, Balazs C. Polymorphisms of the glucocorticoid receptor gene in Graves ophthalmopathy. Br J Ophthalmol. 2008;92(1):131-134. https://doi.org/10.1136/bjo.2007.126789
Lehmann GM, Feldon SE, Smith TJ, Phipps RP. Immune mechanisms in thyroid eye disease. Thyroid. 2008;18(9):959-965. https://doi.org/10.1089/thy.2007.0407
Smith TJ, Tsai CC, Shih MJ, Tsui S, Chen B, Han R, Naik V, King CS, Press C, Kamat S, Goldberg RA, Phipps RP, Douglas RS, Gianoukakis AG. Unique attributes of orbital fibroblasts and global alterations in IGF-1 receptor signaling could explain thyroid-associated ophthalmopathy. Thyroid. 2008;18(9):983-988. https://doi.org/10.1089/thy.2007.0404

Close metadata